PROMISIA HEALTHCARE LIMITED The directors of Promisia Integrative Limited announced today that a substantial grant application to Callaghan Innovation has been approved. The grant will reimburse 40% of the total cost to undertake a 2-year approved programme of research and development.
Chief Scientist Dr Sheena Hunt commented: "Promisia's point of difference is that the company produces natural therapeutic products that are supported by robust scientific evidence of safety and efficacy. Receipt of this grant from Callaghan Innovation allows us to enter the next phase of our extensive R&D programme."
Callaghan Innovation provided financial support for extensive in vitro studies and the human clinical trial of Arthremfrom 2013-2015. Chairman, Stephen Underwood, said that the support of Callaghan Innovation was a critical factor in establishing the scientific credibility of Arthrem, Promisia's flagship product.
Callaghan Innovation is a government agency that supports New Zealand hi-tech businesses. For further information, please contact:
Dr Sheena Hunt, Chief Scientist, on 021 2016104 or Mr Stephen Underwood, Chairman on 027 4993387.
ENDS
Promisia Integrative Limited published this content on 27 April 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 April 2017 07:47:14 UTC.
Public permalinkhttp://www.publicnow.com/view/8B5B41BC214A98741F9AE1177643E7582956DFDF
